Table 3.
Biologic agent level and post-operative complications
| Literature | Study period | Study design | No. of patients | Serum biologic level | End point | Complications | Significant difference? |
|---|---|---|---|---|---|---|---|
| Waterman et al. (2013) [84] | 2000–2010 | Retrospective single-center | 19 UC | Detectable vs. Not (cutoff 1.4 μg/mL) | Overall infectious complications | 3/10 (detectable) vs. 0/9 (not detectable) | No |
| Lau et al. (2015) [82] | 1999–2012 | Retrospective single-surgeon | 60 UC | Detectable vs. Not | 30-day complication | 8/17 (detectable) vs. 17/43 (not) | No for Detectable vs. Not |
| Stratified: (>3 vs. <3 μg/mL)* | 16/47 (>3 μg/mL) vs. 13/76 (<3 μg/mL) | Yes (OR 2.5, P = 0.03) for >3 vs. <3 μg/mL | |||||
| 123 CD | |||||||
| Fumery et al. (2016) [83] | 2010–2014 | Multi-center prospective cohort | 76 CD | >1 and >3 μg/mL | 30-day complication | Only OR reported | No |
| >1 μg/mL: 0.69 (95% CI: 0.21–2.22) | |||||||
| >3 μg/mL: 0.95 (95% CI: 0.28–2.96) |
*
Subgroup analysis of low or undetectable (<3 μg/mL) vs. medium and high (>3 μg/mL). UC, ulcerative colitis; CD, Crohn’s disease; CI, confidence interval.